---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-034529"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T18:40:33.273675+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx inks exclusive license deal with Almirall for ZKN-013; $3M upfront, up to $470M milestones

## Summary
- Upfront payment of $3.0 million; eligible for up to $470.0 million in regulatory and sales milestones.
- Tiered royalties on any future global sales of ZKN-013.
- ZKN-013 is a Phase I ready oral therapy for nonsense mutations causing rare dermatologic diseases.
- Almirall obtains worldwide rights to develop and commercialize ZKN-013.

## SEC filing metadata
- accession: 0001104659-24-034529
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/0001104659-24-034529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/tm248887d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-034529
- JSON: https://secwatch.observer/filing/0001104659-24-034529.json
- Plain text: https://secwatch.observer/filing/0001104659-24-034529.txt

## Key facts
- Material Agreements
  Eloxx Pharmaceuticals, Inc. entered into License Agreement with Almirall, S.A. valued at $3.0 million (effective 2024-03-11).
  - Action: entry
  - Agreement: license
  - Counterparty: Almirall, S.A.
  - Value: $3.0 million
  - Effective: 2024-03-11
  source text: entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/0001104659-24-034529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.